DOI: https://doi.org/10.22141/2224-0721.15.2.2019.166100

Risk factors of recurrent non-functioning pituitary adenomas in patients with growth hormone deficiency

Yu.M. Urmanova, M.Yu. Shakirova, N.T. Rikhsieva, F.S. Khodgaeva

Abstract


Background. Nowadays, a search for diagnostically significant markers of aggressiveness of non­functioning pituitary adenomas remains relevant for further prognosis in the postoperative period. Non­functioning pituitary adenomas without pituitary hypersecretion are the forms of adenohypophysis tumors. In the general population, frequency of non­functioning pituitary adenomas is 50 cases per 1 million people. The purpose of the study is to determine the clinical diagnostic markers of tumor aggressiveness in patients with non­functio­ning pituitary adenomas and growth hormone deficiency, as well as their role in the severity of the neuroendocrine symptoms of the disease. Materials and methods. Under our supervision, there were 87 patients (44 men, 43 women), of them 31 with a verified diagnosis of non­functioning pituitary adenomas after transnasal hypophysectomy. Follow­up was from 1 to 3 years. Results. When patients were distributed in groups depending on histological description of non­functioning pituitary adenomas, those with chromophobe pituitary adenoma prevailed (77.5 %). Non­functioning pituitary ade­nomas in women were associated with obesity, primary and secondary hypothyroidism, secondary hypogonadism, syndrome of persistent galactorrhea­amenorrhea (symptomatic and idiopathic forms), diabetes insipidus, empty sella syndrome and others. In men, non­functioning pituitary adenomas was accompanied by obesity, primary and secondary hypothyroidism, secondary hypogonadism, diabetes insipidus, gynecomastia. The scale developed to determine the markers of aggressiveness of non­functioning pituitary adenomas allowed identifying factors by 3 degrees and developing a set of measures to prevent the recurrence of tumor growth. Conclusions. Markers of aggressiveness of non­functioning pituitary adenomas are: young age of the patient, first symptoms of the disease, large tumor sizes, asymmetry and deformation of the pituitary gland, signs of tumor invasion into adjacent tissues/arteries/cavernous sinus, small cell and/or dark cell chromophobe adenomas, panhypopituitarism.


Keywords


non-functioning pituitary adenomas; growth hormone deficiency; risk factors

References


Molitch ME. Diagnosis and Treatment of Pituitary Adenomas: A Review. JAMA. 2017 Feb 7;317(5):516-524. doi: 10.1001/jama.2016.19699.

Chanson P, Raverot G, Castinetti F, et al. Management of clinically non-functioning pituitary adenoma. Ann Endocrinol (Paris). 2015 Jul;76(3):239-47. doi: 10.1016/j.ando.2015.04.002.

Lake MG, Krook LS, Cruz SV. Pituitary adenomas: an overview. Am Fam Physician. 2013 Sep 1;88(5):319-27.

Raappana A, Koivukangas J, Ebeling T, Pirila T. Incidence of pituitary adenomas in Northern Finland in 1992-2007. J Clin Endocrinol Metab. 2010 Sep;95(9):4268-75. doi: 10.1210/jc.2010-0537.

Katznelson L, Atkinson JL, Cook DM, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly-2011 update. Endocr Pract. 2011 Jul-Aug;17 Suppl 4:1-44.

Besser GM, Burman P, Daly AF. Predictors and rates of treatment-resistant tumor growth in acromegaly. Eur J Endocrinol. 2005 Aug;153(2):187-93. doi: 10.1530/eje.1.01968.

Cury ML, Fernandes JC, Machado HR, Elias LL, Moreira AC, Castro MD. Non-functioning pituitary adenomas: clinical feature, laboratorial and imaging assessment, therapeutic management and outcome. Arq Bras Endocrinol Metabol. 2009 Feb;53(1):31-9.

Mavromati M, Kuhn E, Agostini H, et al. Classification of Patients With GH Disorders May Vary According to the IGF-I Assay. J Clin Endocrinol Metab. 2017 Aug 1;102(8):2844-2852. doi: 10.1210/jc.2017-00202.

Martínez-Méndez JH, Gutiérrez-Acevedo M, Palermo-Garofalo C, et al. Do We Need Hormonal Screening In Patients With Subcentimeter Pituitary Microadenomas? Bol Asoc Med P R. 2015 Apr-Jun;107(2):89-91.

Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectionalstudy in the province of Liège, Belgium. J Clin Endocrinol Metab. 2006 Dec;91(12):4769-75. doi: 10.1210/jc.2006-1668.

Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas:a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010 Mar;72(3):377-82. doi: 10.1111/j.1365-2265.2009.03667.x.

Cury ML, Fernandes JC, Machado HR, Elias LL, Moreira AC, Castro Md. Non-functioning pituitary adenomas: clinical feature, laboratorial and imaging assessment, therapeutic management and outcome. Arq Bras Endocrinol Metabol. 2009 Feb;53(1):31-9.

Tirosh A, Toledano Y, Masri-Iraqi H, et al. IGF-I levels reflect hypopituitarism severity in adults with pituitary dysfunction. Pituitary. 2016 Aug;19(4):399-406. doi: 10.1007/s11102-016-0718-1.

Khalimova ZYu, Kholova DS, Urmanova YuM, Alieva DA, Alimukhamedova GA, Nasirova KhK. Reproductive Function in Patients with Non-functioning Pituitary Adenoma According to the Register of the Republic of Uzbekistan. International Journal of Biomedicine. 2016;6(2):133-135 doi: 10.21103/Article6(2)_ShC1.






Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2019

 

   Seo анализ сайта